• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

手术治疗阴性和阳性淋巴结髓样甲状腺癌后降钙素正常化的时间。

Time to calcitonin normalization after surgery for node-negative and node-positive medullary thyroid cancer.

机构信息

Medical Faculty, Department of General, Visceral and Vascular Surgery, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany.

Department of General, Visceral and Transplantation Surgery, Section of Endocrine Surgery, University of Duisburg-Essen, Essen, Germany.

出版信息

Br J Surg. 2019 Mar;106(4):412-418. doi: 10.1002/bjs.11071. Epub 2019 Feb 6.

DOI:10.1002/bjs.11071
PMID:30725475
Abstract

BACKGROUND

It remains unclear when postoperative serum calcitonin levels should be measured in patients with medullary thyroid cancer (MTC) and, specifically, whether this decision should be based on the preoperative calcitonin level or nodal status.

METHODS

A cohort of patients with previously untreated MTC was studied. Kaplan-Meier analyses, stratified by preoperative calcitonin level, nodal status and number of nodal metastases, were performed to determine time to calcitonin normalization after initial surgery, with statistical analysis by means of the log rank test.

RESULTS

Some 213 patients with node-negative and 182 with node-positive MTC were included in the study. Postoperative calcitonin levels normalized in a mean of 3·5 versus 3·7 days respectively among patients with preoperative calcitonin levels of 10-100 pg/ml (P = 0·815); 4·8 versus 5·3 days in those with preoperative calcitonin levels of 100·1-500 pg/ml (P = 0·026); 5·3 versus 9·9 days in patients with preoperative calcitonin levels of 500·1-1000 pg/ml (P = 0·004); and 6·6 versus 57·7 days among those with preoperative calcitonin levels exceeding 1000 pg/ml (P < 0·001). Calcitonin levels normalized in a mean of 4·7 days when nodal metastasis was not present, 5·2 days in those with one to five nodal metastases, 7·0 days in patients with six to ten nodal metastases, and 57·1 days among patients with more than ten nodal metastases. Postoperative calcitonin normalization curves paralleled each other in patients with node-negative MTC, but diverged in those with node-positive disease and with more nodal metastases.

CONCLUSION

Calcitonin levels typically normalize within 1 week; and within a fortnight in those with node-positive MTC and preoperative calcitonin levels of 500·1-1000 pg/ml. With node-positive MTC and preoperative calcitonin levels exceeding 1000 pg/ml, and with more than ten nodal metastases, calcitonin normalization takes longer.

摘要

背景

目前仍不清楚在甲状腺髓样癌(MTC)患者中应何时测量术后血清降钙素水平,具体而言,这一决定是否应基于术前降钙素水平或淋巴结状态。

方法

研究了一组未经治疗的 MTC 患者。通过 Kaplan-Meier 分析,按术前降钙素水平、淋巴结状态和淋巴结转移数分层,确定初始手术后降钙素正常化的时间,通过对数秩检验进行统计分析。

结果

研究纳入了 213 例淋巴结阴性和 182 例淋巴结阳性的 MTC 患者。术前降钙素水平为 10-100pg/ml 的患者术后降钙素水平分别在 3.5 天和 3.7 天内恢复正常(P=0.815);术前降钙素水平为 100.1-500pg/ml 的患者分别在 4.8 天和 5.3 天内恢复正常(P=0.026);术前降钙素水平为 500.1-1000pg/ml 的患者分别在 5.3 天和 9.9 天内恢复正常(P=0.004);术前降钙素水平超过 1000pg/ml 的患者分别在 6.6 天和 57.7 天内恢复正常(P<0.001)。无淋巴结转移患者的降钙素水平平均在 4.7 天内恢复正常,有 1-5 个淋巴结转移的患者在 5.2 天内恢复正常,有 6-10 个淋巴结转移的患者在 7.0 天内恢复正常,有超过 10 个淋巴结转移的患者在 57.1 天内恢复正常。在淋巴结阴性 MTC 患者中,降钙素正常化曲线相互平行,但在淋巴结阳性疾病和淋巴结转移较多的患者中则有所偏离。

结论

降钙素水平通常在 1 周内恢复正常;在淋巴结阳性 MTC 患者和术前降钙素水平为 500.1-1000pg/ml 的患者中,降钙素水平在两周内恢复正常。在淋巴结阳性 MTC 患者和术前降钙素水平超过 1000pg/ml 以及淋巴结转移超过 10 个的患者中,降钙素恢复正常需要更长的时间。

相似文献

1
Time to calcitonin normalization after surgery for node-negative and node-positive medullary thyroid cancer.手术治疗阴性和阳性淋巴结髓样甲状腺癌后降钙素正常化的时间。
Br J Surg. 2019 Mar;106(4):412-418. doi: 10.1002/bjs.11071. Epub 2019 Feb 6.
2
Serum Calcitonin-Negative Medullary Thyroid Carcinoma: A Case Series of 19 Patients in a Single Center.血清降钙素阴性髓样甲状腺癌:单中心 19 例患者的病例系列。
Front Endocrinol (Lausanne). 2021 Nov 5;12:747704. doi: 10.3389/fendo.2021.747704. eCollection 2021.
3
Preoperative basal calcitonin and tumor stage correlate with postoperative calcitonin normalization in patients undergoing initial surgical management of medullary thyroid carcinoma.在接受初始手术治疗的甲状腺髓样癌患者中,术前基础降钙素和肿瘤分期与术后降钙素正常化相关。
Surgery. 2011 Dec;150(6):1168-77. doi: 10.1016/j.surg.2011.09.043.
4
Medullary thyroid cancer outcomes in patients with undetectable versus normalized postoperative calcitonin levels.降钙素水平术后检测不到与正常的甲状腺髓样癌患者的结局。
Br J Surg. 2021 Sep 27;108(9):1064-1071. doi: 10.1093/bjs/znab106.
5
Cure and survival of sporadic medullary thyroid carcinoma following systematic preoperative calcitonin screening.系统术前降钙素筛查后散发性甲状腺髓样癌的治愈和生存。
Langenbecks Arch Surg. 2019 Jun;404(4):411-419. doi: 10.1007/s00423-019-01764-3. Epub 2019 Mar 22.
6
Long-Term Follow-up in Medullary Thyroid Carcinoma.甲状腺髓样癌的长期随访
Recent Results Cancer Res. 2015;204:207-25. doi: 10.1007/978-3-319-22542-5_10.
7
A Nationwide Study of Multiple Endocrine Neoplasia Type 2A in Norway: Predictive and Prognostic Factors for the Clinical Course of Medullary Thyroid Carcinoma.挪威2A型多发性内分泌腺瘤病的全国性研究:甲状腺髓样癌临床病程的预测和预后因素
Thyroid. 2016 Sep;26(9):1225-38. doi: 10.1089/thy.2015.0673. Epub 2016 Aug 11.
8
Surgical strategy for the treatment of sporadic medullary thyroid carcinoma: our experience.散发性甲状腺髓样癌的手术治疗策略:我们的经验
G Chir. 2012 Nov-Dec;33(11-12):395-9.
9
CALCITONIN SECRETORY INDEX AND UNSUSPECTED NODAL DISEASE IN MEDULLARY THYROID CARCINOMA.降钙素分泌指数与甲状腺髓样癌隐匿性淋巴结疾病。
Endocr Pract. 2018 May;24(5):460-467. doi: 10.4158/EP-2017-0236.
10
Biomarker-based risk stratification for previously untreated medullary thyroid cancer.基于生物标志物的未经治疗的甲状腺髓样癌风险分层。
J Clin Endocrinol Metab. 2010 Jun;95(6):2655-63. doi: 10.1210/jc.2009-2368. Epub 2010 Mar 25.

引用本文的文献

1
[Update on medullary thyroid carcinoma-What is relevant for surgeons?].[甲状腺髓样癌的最新进展——对外科医生有何重要意义?]
Chirurgie (Heidelb). 2025 May 19. doi: 10.1007/s00104-025-02289-w.
2
MEN2: surgical precision in the era of precision medicine.MEN2:精准医学时代的手术精准性。
Endocr Relat Cancer. 2025 Jun 6;32(6). doi: 10.1530/ERC-24-0251. Print 2025 Jun 1.
3
Long-Term Follow-Up in Medullary Thyroid Carcinoma Patients.甲状腺髓样癌患者的长期随访
Recent Results Cancer Res. 2025;223:267-291. doi: 10.1007/978-3-031-80396-3_11.
4
Surgical Treatment of Medullary Thyroid Cancer.甲状腺髓样癌的外科治疗
Recent Results Cancer Res. 2025;223:247-266. doi: 10.1007/978-3-031-80396-3_10.
5
Epidemiology, Clinical Presentation, and Diagnosis of Medullary Thyroid Carcinoma.甲状腺髓样癌的流行病学、临床表现及诊断
Recent Results Cancer Res. 2025;223:93-127. doi: 10.1007/978-3-031-80396-3_4.
6
Management of medullary thyroid cancer based on variation of carcinoembryonic antigen and calcitonin.基于癌胚抗原和降钙素变化的甲状腺髓样癌的管理。
Front Endocrinol (Lausanne). 2024 Oct 10;15:1418657. doi: 10.3389/fendo.2024.1418657. eCollection 2024.
7
Treatment and management of medullary thyroid microcarcinoma: a 10-year retrospective study from a single center.甲状腺髓样微癌的治疗和管理:单中心十年回顾性研究。
Endocrine. 2024 Dec;86(3):1081-1089. doi: 10.1007/s12020-024-03958-2. Epub 2024 Jul 15.
8
Time Kinetics and prognosis roles of calcitonin after surgery for medullary thyroid carcinoma.降钙素在甲状腺髓样癌手术后的时间动力学和预后作用。
World J Surg Oncol. 2024 May 6;22(1):121. doi: 10.1186/s12957-024-03397-3.
9
Changes of biochemical factors and the effect on recurrence of medullary thyroid carcinoma after surgery.甲状腺髓样癌术后生化因素的变化及其对复发的影响。
Heliyon. 2024 Apr 17;10(8):e29857. doi: 10.1016/j.heliyon.2024.e29857. eCollection 2024 Apr 30.
10
Serum Biochemical Markers for Medullary Thyroid Carcinoma: An Update.甲状腺髓样癌的血清生化标志物:最新进展
Cancer Manag Res. 2024 Apr 8;16:299-310. doi: 10.2147/CMAR.S440477. eCollection 2024.